Exelixis outlines zanza CRC launch plans as 2026 revenue guidance midpoint is lowered by $50M (NASDAQ:EXEL)
· seekingalpha.com
Exelixis (EXEL) Q2 2026 earnings call recap: lowered revenue guidance on slower NET ramp, cabo trends, zanzalintinib CRC filing, and catalysts—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...